Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation  by Antin, Joseph H. et al.
P
C
S
I
c
f
p
a
t
e
C
d
i
Biology of Blood and Marrow Transplantation 11:213–222 (2005)
 2005 American Society for Blood and Marrow Transplantation
1083-8791/05/1103-0007$30.00/0
doi:10.1016/j.bbmt.2004.12.330
Brotective Antibody Responses to Pneumococcal
onjugate Vaccine after Autologous Hematopoietic
tem Cell Transplantation
Joseph H. Antin,1 Eva C. Guinan,1 David Avigan,2 Robert J. Soiffer,1 Robin M. Joyce,2
Victoria J. Martin,3 Deborah C. Molrine3
1Departments of Adult Oncology and Pediatric Oncology, Dana-Farber Canter Institute, Boston, Massachusetts;
2Hematologic Malignancy Bone Marrow Transplant Program, Beth Israel Deaconess Medical Center, Boston,
Massachusetts; 3Massachusetts Biologic Laboratories, University of Massachusetts Medical School, Jamaica Plain,
Massachusetts
Correspondence and reprint requests: Deborah C. Molrine, MD, Massachusetts Biologic Laboratories, University of
Massachusetts Medical School, 305 South St., Jamaica Plain, MA 02130 (e-mail: deborah.molrine@umassmed.edu).
Received June 29, 2004; accepted December 16, 2004
ABSTRACT
Patients undergoing autologous hematopoietic stem cell transplantation (autoHCT) are at increased risk for
infection with Streptococcus pneumoniae and have impaired antibody responses to pneumococcal polysaccharide
vaccines. We performed this study to examine the ability of autoHCT patients to respond to a heptavalent
pneumococcal conjugate vaccine (PCV7) given after transplantation and to determine whether there was a
potential benefit of immunizing these patients before stem cell collection. Sixty-one patients scheduled for
autoHCT were randomized to receive either PCV7 or no vaccine before stem cell collection. After stem cell
reinfusion, all study patients were immunized with PCV7 at 3, 6, and 12 months. Pneumococcal immuno-
globulin G antibody concentrations were measured at the time of each immunization and 1 month after the
12-month dose. Serotype-specific pneumococcal antibody concentrations were significantly higher in patients
immunized with PCV7 before stem cell collection compared with patients not immunized before their stem
cells were collected for 6 of 7 serotypes at 3 months, 6 of 7 serotypes at 6 months, 4 of 7 serotypes at 12 months,
and 3 of 7 serotypes at 13 months. After the 3-dose series of PCV7 after autoHCT,>60% of study patients had
protective concentrations of antibody to all 7 vaccine serotypes regardless of immunization before stem cell
collection. Pneumococcal conjugate vaccine is immunogenic in autoHCT patients and may be an effective
strategy to prevent invasive disease after transplantation.
© 2005 American Society for Blood and Marrow Transplantation
KEY WORDS
Hematopoietic cell transplantation ● Pneumococcal conjugate vaccine ● Immunization ●
Autologous
s
H
m
c
d
e
[
p
s
dNTRODUCTION
Patients undergoing autologous hematopoietic
ell transplantation (autoHCT) are at increased risk
or infection with Streptococcus pneumoniae and other
olysaccharide-encapsulated organisms [1-4]. After
utologous and allogeneic stem cell transplantation,
here is a decline in speciﬁc antibodies, and the recov-
ry of B-cell and T-cell function is delayed [5-8]
urrent recommendations to prevent pneumococcal
isease in hematopoietic cell transplant (HCT) recip-
ents include the use of 23-valent pneumococcal poly- v
B&MTaccharide vaccine at 12 and 24 months after HCT [9].
owever, most HCT patients respond poorly to im-
unization with unconjugated polysaccharide vac-
ines, because immune responses to T cell–indepen-
ent antigens are slow to mature after transplantation
ven when immunization is delayed until 12 months
10-13].
Polysaccharide conjugate vaccines link capsular
olysaccharides to protein carriers and enhance poly-
accharide antibody responses through T cell–depen-
ent mechanisms [14,15]. Polysaccharide conjugate
accines to Haemophilus inﬂuenzae type b (HIB) and
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2pneumoniae have been shown to be effective in provid-
ng protection from invasive disease in infant populations
nable to respond adequately to polysaccharide vaccines
16-18]. We and others have shown that HIB conjugate
nd, more recently, pneumococcal conjugate vaccines
re immunogenic in non–T cell–depleted allogeneic
one marrow transplantation (BMT) patients [19-21]. In
his study, the ability of autoHCT patients to respond to
neumococcal conjugate vaccine was examined. We also
ought to determine whether immunization of these
atients before stem cell collection enhanced antibody
esponses to vaccine administered after transplantation.
ATERIALS AND METHODS
atient Population
Patients were recruited during ambulatory visits to
he oncology centers at Brigham and Women’s Hos-
ital, Dana-Farber Cancer Institute, Children’s Hos-
ital, and Beth Israel Deaconess Medical Center (all in
oston, MA). Eligible patients were those older than 2
ears of age with an underlying diagnosis of a hema-
ologic malignancy and who were scheduled to receive
n autologous stem cell transplant. Patients who gave
history of immunization with 23-valent pneumococ-
al polysaccharide vaccine within the previous 6 years
ere excluded from study participation. Informed
onsent was obtained from the patient or his or her
arent or guardian. The study protocol was approved
y the institutional review boards of all participating
nstitutions. Eligibility criteria, outcome variables, and
he analysis plan were determined before study initi-
tion. Patients were conditioned for transplantation
ccording to diagnosis and current protocols.
Patients enrolled in the study were randomized to
eceive a dose of heptavalent pneumococcal conjugate
accine (PCV7, Prevnar; Wyeth Lederle Laborato-
ies, Pearl River, NY) approximately 7 to 10 days
efore stem cell collection or no vaccine before stem
ell collection. Randomization of patients was strati-
ed according to age (pediatric versus adult) and used
permuted block design. Prelicensure lots of PCV7
ontaining serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F
ndividually conjugated to a nontoxic variant of diph-
heria toxin (CRM197) were used. After reinfusion of
tem cells (transplantation), all study patients were
mmunized with PCV7 at 3, 6, and 12 months. Blood
amples were collected at the time of each immuniza-
ion and a mean of 5 weeks (range, 2-11 weeks) after
he 12-month dose of vaccine (designated as the 13-
onth sample). For patients randomized to receive a
ose of vaccine before stem cell collection, a blood
ample for baseline pneumococcal antibody concen-
rations was collected on the day of immunization.
he baseline sample was collected a mean of 10 daysrange, 6 to 25 days) before stem cell collection. A c
14econd sample was obtained from these patients at the
ime of stem cell collection to evaluate the antibody
esponse to the single dose of PCV7 given before stem
ell collection. For the patients randomized to receive
o vaccine before stem cell collection, a blood sample
or baseline pneumococcal antibody concentrations
as collected near the day of initial stem cell collec-
ion (mean of 2.4 days before stem cell collection;
ange, 18 days before to 9 days after the initial collec-
ion). The serum from these samples was stored at
80°C until assay. Laboratory assays were performed
n coded samples by personnel blinded to a patient’s
mmunization group assignment.
dverse Event Monitoring
All study patients completed standardized vaccina-
ion report cards at 24, 48, and 72 hours after each
mmunization. Local injection site reactions of red-
ess, swelling, and arm tenderness were scored as
ild, moderate, or severe according to the size of the
eaction and restriction of arm movement. Systemic
eactions that were monitored consisted of fever,
eadache, malaise, joint pain, or other. Fever was
eﬁned as an oral temperature of 37.2°C.
ntibody Assays
Immunoglobulin (Ig)G antibodies to serotype-
peciﬁc pneumococcal capsular polysaccharides were
easured by a C-polysaccharide (CPS)-absorbed en-
yme-linked immunosorbent assay [21]. IgG antibody
oncentrations were measured for the 7 vaccine sero-
ypes (4, 6B, 9V, 14, 18C, 19F, and 23F), with a lower
imit of detection of 10 ng/mL for each serotype. The
eference standard of the assay was US standard ref-
rence serum lot 89-SF from the Center for Biological
valuation and Review (Food and Drug Administra-
ion, Bethesda, MD).
tatistical Analysis
Antibody results were log-transformed for statis-
ical analyses. The primary outcome of the study was
comparison of the serotype-speciﬁc antibody con-
entrations of patients immunized before stem cell
ollection with those of patients not immunized be-
ore stem cell collection after receipt of 3 doses of
CV7 after transplantation. Comparisons of geomet-
ic mean antibody concentrations were also performed
t 3, 6, and 12 months after HCT between the 2
mmunization groups. Antibody concentrations below
he limit of assay quantitation were assigned values of
ne half the lower limit. Comparisons of geometric
ean antibody concentrations between immunization
roups were performed by 2-tailed t tests. The pro-
ortion of patients in each immunization group with
rotective concentrations of antibody (deﬁned as a
oncentration 0.35 g/mL to all 7 vaccine sero-
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Bypes) was compared by Fisher exact test. Assessment
f the effect of immunization group, sex, age at trans-
lantation, underlying diagnosis, source of stem cells,
aseline pneumococcal antibody concentrations, con-
itioning regimen, total body irradiation, and ex vivo
anipulation on posttransplantation serotype-speciﬁc
ntibody concentrations was determined by multivar-
ate stepwise linear regression analyses.
ESULTS
atient Population
Sixty-one patients were enrolled in the study, of
hom 45 were evaluable after transplantation. Evalu-
ble patients were deﬁned as those who had survived
isease free to at least 3 months after transplantation.
f the 16 patients excluded from analysis, 11 were
andomized to the group unimmunized before stem
ell collection and never received study vaccine. Of
hese 11 patients, 4 died from disease or complications
f transplantation before 3 months, 4 relapsed before
months, 1 patient had the type of transplantation
hanged after study enrollment, 1 patient had persis-
ent thrombocytopenia and could not receive 3-month
mmunizations, and 1 patient moved away and with-
rew from the study. Five patients in the group im-
unized before stem collection were excluded from
nalysis: 2 patients had their transplantation post-
oned, 1 patient was subsequently enrolled on another
rotocol and withdrew from participation, 1 patient
issed 3-month immunizations, and 1 patient was
emoved for the protocol violation of having received
neumococcal vaccine 2 years before stem cell collec-
ion. Of the 45 evaluable patients, clinical character-
stics were similar between the 2 immunization
roups, as shown in Table 1. Most patients mobilized
or peripheral blood stem cell (PBSC) collection re-
eived high-dose cyclophosphamide followed by gran-
locyte colony-stimulating factor (G-CSF). There
ere no signiﬁcant differences between groups in
erms of age at time of transplantation, sex, underlying
iagnosis, source of stem cell infusion at transplanta-
ion, conditioning regimen, receipt of total body irra-
iation, or ex vivo manipulation.
ntibody Responses of Patients Immunized with
neumococcal Conjugate Vaccine before Stem
ell Collection
Twenty-ﬁve of the 45 eligible patients had been
andomized to receive a single dose of PCV7 before
tem cell collection. Immunization was given a mean
f 9.3 days (range, 6-17 days) before the start of stem
ell collection. Twenty-two of the 25 patients immu-
ized before stem cell collection had serum samples
oth from before immunization (baseline) and from
he time of stem cell collection. Fold increases in t
B&MTeometric mean antibody concentrations ranged from
.77 for serotype 19F to 1.8 for serotype 14. After
mmunization, geometric mean antibody concentra-
able 1. Characteristics of Autologous Stem Cell Transplantation
tudy Patients
Characteristic
Group
Immunized
before Stem Cell
Collection
(n  25)
Not Immunized
before Stem Cell
Collection
(n  20)
edian age, y (range) 44 (4-69) 46 (13-69)
ale/female 14/11 10/10
iagnosis, n (%)
NHL 19 (76) 11 (55)
HD 4 (16) 4 (20)
CLL 1 (4) 2 (10)
AML 0 (0) 2 (10)
ALL 1 (4) 1 (5)
ource of stem cell
infusion (n)
PBSCs 8 5
Bone marrow 11 10
PBSCs and bone
marrow 6 5
onditioning regimen,
n (%)
CTX 10 (40) 9 (45)
CTX/VP-16 1 (4) 1 (5)
CTX/BCNU/VP-16 13* (52) 8 (40)
CTX/busulfan 0 (0) 2 (10)
CTX/thiotepa/
carboplatin 1 (4) 0 (0)
otal body irradiation,
n (%) 11 (44) 10 (50)
x vivo manipulation,
n (%)
CALLA 1 (4) 1 (5)
B1B5J5  BRC 10 (40) 9 (45)
ubjects evaluable at
Study time points (n)
3 mo 25 20
6 mo 19† 19‡
12 mo 18§ 19
13 mo 15 18¶
HL indicates non-Hodgkin lymphoma; HD, Hodgkin disease;
CLL, chronic lymphatic leukemia; AML, acute myelogenous
leukemia; ALL, acute lymphatic leukemia; PBSCs, peripheral
blood stem cells; CTX, cyclophosphamide; BCNU, carmustine;
CALLA, common acute lymphoblastic leukemia antigen; VP-
16, etoposide; B1B5J5 BRC, monoclonal antibody treatment
of stem cells with anti-B1 (CD20), anti-B5 and J5 (anti-CD10)
plus baby rabbit complement.
Two patients in the group immunized before stem cell collection
were also conditioned with dexamethasone/ifosfamide/carbopla-
tin/VP-16.
Five patients had a relapse of underlying malignancy, and 1 patient
had refractory thrombocytopenia.
One patient had a relapse of underlying malignancy.
One patient had a relapse of underlying malignancy.
Two patients had a relapse of underlying malignancy, and 1 patient
had a protocol violation.
One patient did not return for the ﬁnal blood draw.ions were higher for all serotypes except for serotype
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29F, which declined from 3.30 to 3.06 g/mL (P 
023 by paired t test). The increases for the other 6
erotypes were not statistically signiﬁcant, with geomet-
ic mean antibody concentrations of 0.86 g/mL for
erotype 4, 2.43 g/mL for serotype 6B, 0.99 g/mL for
erotype 9V, 3.23 g/mL for serotype 14, 1.16 g/mL
or serotype 18C, and 2.29 g/mL for serotype 23F at
he time of stem cell collection.
ntibody Responses to Pneumococcal Conjugate
accine Administered after Stem Cell
ransplantation by Immunization Group
The primary outcome of the study was a compar-
son of antibody concentrations between the immuni-
ation groups after receipt of PCV7 vaccine at 3, 6,
nd 12 months after autoHCT. Patients who were
mmunized with PCV7 before stem cell collection had
onsistently higher pneumococcal antibody concen-
rations to vaccine serotypes after HCT compared
igure 1. Effect of immunization with heptavalent pneumococcal co
o PCV7 administered after autoHCT. Geometric mean IgG antib
CV7 before stem cell collection (——) were compared with those
y the arrowheads, all study patients received PCV7 3, 6, and 12
igniﬁcantly higher for the group immunized before stem cell colle
.05; t test).ith patients not immunized before stem cells were e
16ollected (Figure 1). At 13 months, after receipt of 3
oses of PCV7 at 3, 6, and 12 months after HCT,
eometric mean IgG pneumococcal antibody concen-
rations were higher in patients immunized before
tem cell collection compared with those immunized
fter transplantation only, and this reached signiﬁ-
ance for serotypes 18C, 19F, and 23F. Signiﬁcant
ifferences in serotype-speciﬁc pneumococcal IgG an-
ibody concentrations between the immunization
roups were also seen earlier after HCT after receipt
f 1 and 2 doses of PCV7. Geometric mean antibody
oncentrations in patients immunized before stem cell
ollection were signiﬁcantly higher for 6 of the 7
accine serotypes at 6 months and for 4 of the 7
erotypes at 12 months after HCT (Table 2). Of note,
eometric mean IgG pneumococcal antibody concen-
rations at 3 months before administration of post-
ransplantation doses of pneumococcal conjugate vac-
ine were signiﬁcantly higher for all vaccine serotypes
e vaccine (PCV7) before stem cell collection on antibody responses
centrations to the serotypes of PCV7 of patients immunized with
ents not immunized before stem cell collection (- - -). As indicated
after autoHCT. *Geometric mean antibody concentrations were
ompared with those not immunized before stem cell collection (Pnjugat
ody con
of pati
months
ction cxcept serotype 9V in patients immunized before stem
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Bell collection. Geometric mean IgG pneumococcal
ntibody concentrations at 3 months ranged from
.87 g/mL (serotype 4) to 5.39 g/mL (serotype 14)
n the group that was immunized before stem cell
ollection, compared with 0.35 g/mL (serotype 4) to
.74 g/mL (serotype 14) for the group that was not
mmunized before stem cell collection (Table 2).
The proportion of patients in each immunization
roup with protective IgG concentrations to all 7
accine serotypes was also compared at 3, 6, 12, and 13
onths after transplantation. An IgG serotype–spe-
iﬁc antibody concentration of 0.35 g/mL is a cal-
ulated threshold concentration considered protective
n the basis of analyses of recent clinical trials [22,23].
s shown in Table 3, the proportion of patients with
rotective concentrations to all 7 vaccine serotypes
as higher at each of the measured time points in
atients immunized before stem cell collection; this
eached signiﬁcance at 6 months after transplantation
68% versus 32%; P  .03). Regardless of preharvest
able 2. Comparison of Serotype-Speciﬁc Pneumococcal Antibody Conce
fter AutoHCT† between Patients Immunized before Stem Cell Collectio
Serotype Group 3
4 Unimmunized 0.35 (0.21-0.58)
Immunized 0.87 (0.58-1.32)
P value .005
6B Unimmunized 1.12 (0.65-1.93)
Immunized 3.74 (2.04-6.87)
P value .005
9V Unimmunized 0.51 (0.30-0.85)
Immunized 1.12 (0.61-2.05)
P value .053
14 Unimmunized 1.74 (0.97-3.14)
Immunized 5.39 (2.71-10.7)
P value .016
18C Unimmunized 0.50 (0.29-0.85)
Immunized 1.84 (1.03-3.30)
P value .002
19F Unimmunized 1.36 (0.75-2.45)
Immunized 2.89 (1.99-4.18)
P value .024
23F Unimmunized 0.59 (0.35-0.98)
Immunized 2.70 (1.44-5.06)
P value <.0001
Data are geometric mean antibody concentrations (g/mL) (95%
Patients in both immunization groups were immunized with PC
measurement were collected at the time of each immunization
able 3. Comparison of the Percentage of Patients Protected to All 7 V
Months after
AutoHCT
No. Vaccine Doses Received
after AutoHCT
Immun
Cell C
3 0 6
6 1 6
12 2 6
13 3 8Serum not available on 1 patient.
B&MTmmunization,60% of patients who received 3 doses
f PCV7 after autoHCT had protective concentra-
ions at 13 months.
actors Affecting Pneumococcal Antibody
oncentrations after Transplantation
To determine whether other clinical factors af-
ected pneumococcal antibody concentrations after
utoHCT, multiple stepwise linear regression analy-
es were performed. The effects of immunization be-
ore stem cell collection, age at transplantation, sex,
iagnosis, baseline pneumococcal antibody concentra-
ions, source of stem cell infusion (PBSCs or bone
arrow), receipt of total body irradiation, type of
onditioning before transplantation, and ex vivo stem
ell manipulation on serotype-speciﬁc antibody con-
entrations at 3, 6, 12, and 13 months were deter-
ined. In the stepwise selection process, only vari-
bles with a signiﬁcance level .05 were allowed to
nter into the model, and variables were removed if
s* after Immunization with Pneumococcal Conjugate Vaccine (PCV7)
PCV7 and Patients Not Immunized before Stem Cell Collection
Months after Transplantation
6 12 13
5 (0.15-0.43) 0.44 (0.21-0.93) 1.06 (0.48-2.32)
9 (0.47-1.70) 1.39 (0.72-2.68) 2.85 (1.29-6.30)
.003 .021 .070
7 (0.31-1.08) 2.10 (0.98-4.49) 2.36 (0.91-6.11)
0 (1.37-5.72) 1.75 (0.92-3.32) 8.09 (3.50-18.7)
.001 .702 .052
2 (0.26-0.68) 0.83 (0.43-1.61) 1.08 (0.48-2.44)
9 (0.59-2.84) 1.75 (0.82-3.72) 2.77 (1.32-5.84)
.015 .125 .084
1 (0.78-3.33) 1.76 (0.91-3.42) 3.35 (1.67-6.70)
4 (2.01-10.2) 4.05 (2.04-8.09) 6.54 (3.01-14.2)
.053 .075 .180
3 (0.23-1.22) 0.57 (0.31-1.05) 0.81 (0.43-1.53)
4 (1.07-3.89) 2.09 (1.17-3.74) 3.27 (1.75-6.09)
.001 .003 .002
4 (0.48-2.29) 1.15 (0.55-2.41) 2.16 (0.95-4.95)
6 (1.51-5.05) 3.66 (2.25-5.94) 7.61 (3.45-16.8)
.046 .010 .028
9 (0.26-1.34) 0.83 (0.32-2.12) 1.23 (0.48-3.16)
4 (1.43-6.50) 3.44 (1.76-6.72) 6.66 (2.54-17.5)
.004 .016 .013
ence interval).
, 6, and 12 months after autoHCT. Serum samples for antibody
ean of 5 weeks after the 12-month dose.
erotypes* after AutoHCT
fore Stem
on, % (n)
Not Immunized before Stem
Cell Collection, % (n) P Value
25) 40 (8/20) .24
19) 32 (6/19) .03
17)† 47 (9/19) .34
15) 61 (11/18) .13ntration
n with
0.2
0.8
0.5
2.8
0.4
1.2
1.6
4.5
0.4
2.0
1.0
2.7
0.5
3.0
conﬁd
V7 at 3accine S
ized be
ollecti
0 (15/
8 (13/
5 (11/
7 (13/
IgG concentration 0.35 g/mL to serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F.217
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2heir signiﬁcance level was 0.100. All patients who
eceived total body irradiation had ex vivo manipula-
ion of their stem cells; therefore, we chose to use total
ody irradiation as the variable in the regression
odel.
Higher baseline pneumococcal antibody concentra-
ions and being in the group immunized before stem cell
ollection were the 2 variables consistently indepen-
ently associated with higher serotype-speciﬁc pneumo-
occal antibody concentrations after autoHCT (Table 4).
or all 7 serotypes, higher baseline antibody concentra-
ions measured before stem cell collection were signiﬁ-
antly associated with posttransplantation concentra-
ions at all measured time points except for serotype 6B
t 12 months. Being in the group immunized before
tem cell collection was independently signiﬁcantly as-
ociated with higher pneumococcal antibody concentra-
ions for serotypes 4, 6B, 14, 18C, and 23F at 3 months;
erotypes 4, 6B, 14, 18C, and 23F at 6 months; serotypes
4 and 18C at 12 months; and serotype 18 at 13 months
Table 4). No other variable was consistently indepen-
ently associated with higher pneumococcal antibody
oncentrations for multiple serotypes after autoHCT.
Given the signiﬁcant association of baseline
neumococcal antibody concentrations with post-
ransplantation concentrations, we compared the
aseline concentrations between the 2 immunization
roups. Baseline geometric mean IgG pneumococcal
ntibody concentrations of patients immunized before
tem cell collection were signiﬁcantly higher com-
able 4. Final Multivariate Stepwise Regression Analyses* for Serotype
Serotype Variable 3 mo
4 Baseline 1.85 (1.60-2.14)
Group 1.53 (1.02-2.29)
6B Baseline 1.75 (1.42-2.15)
Group 1.96 (1.01-3.78)
Age Tx
CTX only
9V Baseline 1.79 (1.42-2.25)
CTBCVP
14 Baseline 1.92 (1.51-2.45)
Group 2.87 (1.41-5.82)
PBSC
18C Baseline 1.84 (1.48-2.29)
Group 2.00 (1.05-3.90)
19F Baseline 1.86 (1.61-2.14)
Alt cond 2.32 (1.18-4.59)
Age Tx
23F Baseline 1.67 (1.36-2.05)
Group 2.32 (1.19-4.54)
CTX only 0.47 (0.25-0.87)
ata are odds ratio (95% conﬁdence interval).
Variables considered for entry into the model were group (0, no
collection); baseline pneumococcal antibody concentration me
transplantation (age Tx); type of stem cell infusion (PBSC/marr
conditioning regimen (cyclophosphamide [CTX] only, CTX/car
as all other conditioning regimens noted in Table 1). All variabared with those from patients in the group not im- t
18unized before stem cell collection for serotypes 4
0.59 versus 0.26 g/mL; P  .049), 6B (1.55 versus
.60 g/mL; P  .046), 9V (0.85 versus 0.31 g/mL;
 .028), 18C (1.37 versus 0.50 g/mL; P  .020),
9F (3.30 versus 0.93 g/mL; P  .009), and 23F
1.43 versus 0.41 g/mL; P  .009). Baseline geomet-
ic mean IgG concentrations for serotype 14 were not
igniﬁcantly different between the 2 immunization
roups (1.40 versus 1.25 g/mL; P  .80). This dif-
erence in baseline pneumococcal antibody concentra-
ions between the 2 immunization groups was unex-
ected, although the study protocol did not specify
hat the samples for baseline pneumococcal antibody
oncentrations from the 2 groups should be obtained
n the same day before stem cell collection. The mean
SD time interval of serum sample collection for
aseline pneumococcal antibody concentrations rela-
ive to the date of stem cell collection was 10.0  4.3
ays for the group immunized before stem cell collec-
ion and was 2.4  6.2 days in the group not immu-
ized before stem cell collection, and this interval
ifference was signiﬁcant between groups (P .0001).
herefore, univariate linear regression analyses were
erformed to examine the effect of immunization
roup assignment, the interval of time between the
aseline sample collection date and the date of stem
ell collection, age, sex, and diagnosis on baseline
erotype-speciﬁc pneumococcal antibody concentra-
ions. Being randomized to the group immunized be-
ore stem cell collection and having an increased in-
c Pneumococcal Antibody Concentrations Measured after AutoHCT
mo 12 mo 13 mo
.56-2.35) 2.11 (1.61-2.76) 1.83 (1.32-2.55)
.23-3.91)
.48-2.30) 1.72 (1.18-2.50)
.41-5.58)
.93-0.991)
0.36 (0.15-0.92)
.40-2.33) 1.83 (1.45-2.32) 1.74 (1.27-2.38)
2.21 (1.09-4.46)
.89-2.96) 1.82 (1.43-2.32) 1.43 (1.07-1.91)
.53-5.58) 2.35 (1.16-4.75)
2.88 (1.22-6.83)
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before stem cell collection (baseline); sex (male/female); age at
tal body irradiation (yes/no); diagnosis (leukemia/lymphoma); and
/VP-16 [CTBCVP], or alternative conditioning [Alt cond], deﬁned
he ﬁnal model had P values .05.-Speciﬁ
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Pneumococcal Conjugate Immunization in Autologous HCT
Bollection and the date of stem cell collection were
igniﬁcantly associated with higher baseline antibody
oncentrations for 6 of 7 and all 7 serotypes, respec-
ively. However, after controlling for the timing of
aseline sample collection in a multivariate linear re-
ression analysis, the immunization group variable
as no longer statistically signiﬁcantly associated with
igher baseline pneumococcal antibody concentra-
ions.
afety and Tolerability of Pneumococcal
onjugate Vaccine
The heptavalent pneumococcal conjugate vaccine
as well tolerated in patients both before stem cell
ollection and after autoHCT. Of the 35 study pa-
ients who had completed vaccine report cards at 3, 6,
nd 12 months, 28 (80%) reported a reaction at the
-month immunization. Eighteen (64%) of these 28
eported reactions at 6 and 12 months, and 10 (36%)
eported a reaction at 6 or 12 months. The reactions
eported were often similar to the 3 month reaction in
ype and degree of severity. Seven patients (20%) had
o reaction to the 3-month immunization; 3 of the 7
eported no reactions after receipt of the 6- and 12-
onth doses of vaccine, whereas 4 had a reaction at
ither 6 or 12 months. There was no trend for reac-
ions to increase in severity with an increasing number
f doses.
The most frequent local adverse event reported
ithin 72 hours of immunization was pain in the arm
hat received vaccine injections. Forty-three percent
f patients immunized before stem cell collection re-
orted pain, as did 68%, 64%, and 69% of all study
atients at 3, 6, and 12 months, respectively, after
utoHCT. Severe pain restricting arm movement was
eported by 7% to 13% after each immunization.
edness and swelling at the injection site was reported
y 10% to 40% of patients after each immunization
nd did not increase in frequency with an increasing
umber of doses. Fever was reported by 30% of
atients after each injection; all temperatures recorded
xcept 1 were 100.6°F. One patient reported a tem-
erature of 102.8°F at 72 hours after his 3-month
mmunization, with concurrent symptoms of chills,
alaise, joint pain, and cough. He was evaluated and
laced on antibiotics for his respiratory symptoms,
nd he subsequently recovered. Other systemic com-
laints such as headache, malaise, joint pain, and mus-
le aches were reported by approximately 25% of
atients after each immunization. No serious adverse
vent related to immunization was reported.
ISCUSSION
Infections with polysaccharide-encapsulated bac-
eria such as S pneumoniae are not uncommon after a
B&MTematopoietic stem cell transplantation, even though
he risk after autoHCT seems to be less than the risk
fter allogeneic HCT. A recent prospective survey
ssessed the incidence of invasive pneumococcal in-
ection after autologous BMT and PBSC transplanta-
ion to be 3.81 1000 transplantations, compared with
.05 1000 transplantations after allogeneic BMT and
BSC transplantation [2]. These rates of invasive dis-
ase support measures to prevent pneumococcal in-
ections after HCT. Until recently, unconjugated
neumococcal polysaccharide vaccines were the only
accines available for recommended use in HCT pa-
ients, even though responses to these vaccines are
mpaired in most patients. Data from a recent study
onducted in non–T-cell–depleted allogeneic BMT
atients demonstrated that a pneumococcal conjugate
accine was immunogenic in this high-risk group:
ost patients achieved protective concentrations after
3-dose series [21]. In addition, immunization of
ealthy donors with pneumococcal conjugate vaccine
efore bone marrow harvest signiﬁcantly enhanced
ecipients’ antibody responses to posttransplantation
oses of vaccine. Thus, in this study, we examined the
ffect of immunization with a pneumococcal conju-
ate vaccine before stem cell collection on patients’
bility to respond to pneumococcal conjugate vaccine
dministered at 3, 6, and 12 months after autoHCT.
neumococcal antibody concentrations produced af-
er 1, 2, and 3 posttransplantation doses of PCV7 were
ompared between patients immunized before stem
ell collection and patients not immunized before
tem cell collection.
Patients who received pneumococcal conjugate
accine before stem cell collection had signiﬁcantly
igher antibody concentrations to 6 of the 7 vaccine
erotypes at 3 and 6 months after autoHCT compared
ith patients who received vaccine after transplanta-
ion only beginning at 3 months. After the third dose
f PCV7 at 12 months, IgG geometric mean antibody
oncentrations were still signiﬁcantly higher for sero-
ypes 18C, 19F, and 23F in the group immunized
efore stem cell collection. The proportion of patients
ith a protective antibody concentration to all vaccine
erotypes was also higher in the group immunized
efore stem cell collection; 60% to 87% of patients
ere protected between 3 and 13 months after trans-
lantation. In contrast, protective concentrations to
ll 7 serotypes were not achieved in most patients
mmunized after transplantation only until 13 months,
fter completion of the 3-dose series. These results
uggest that immunization before stem cell collection
eneﬁts patients in the early months after autoHCT.
hese ﬁndings conﬁrm results seen in a previous
tudy conducted in autoBMT patients [24]. In that
mall, nonrandomized study of similar design, signif-
cantly higher antibody concentrations were seen after
utoHCT to HIB-conjugate vaccine at 3 months and
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2o tetanus toxoid vaccine at 3 and 6 months in patients
mmunized with these vaccines before bone marrow
arvest compared with patients who were not immu-
ized before harvest.
These data suggest that a strategy to immunize
utologous stem cell donors before stem cell collec-
ion with PCV7 followed by additional doses of pneu-
ococcal conjugate vaccine after transplantation
hould be considered. For both autologous and allo-
eneic stem cell transplantation patients, an approach
o immunize with multiple doses of pneumococcal
onjugate vaccine is likely to produce more consistent
ntigen-speciﬁc antibody responses by expanding the
umber of carrier-speciﬁc T-helper cells, which in
urn enhance the production of antibody from po-
ysaccharide-speciﬁc B cells [25]. The ability of mul-
iple doses of PCV7 to prime for increased antibody
esponses and reduce invasive pneumococcal disease
as been demonstrated in infants, a population whose
mmature immune system also places them at high risk
or pneumococcal disease [18].
Our ﬁndings also expand the immunization liter-
ture on patients who receive autologous PBSC trans-
lants (autoPBSCT). At least half of the enrolled pa-
ients underwent PBSC transplantation with or
ithout BMT. Transplantation with PBSC results in
ore rapid reconstitution of hematopoiesis compared
ith BMT [26,27]. Functional immune recovery may
lso be enhanced in recipients of autoPBSCT com-
ared with autoBMT, although ﬁndings from previ-
us studies have not shown this consistently. In 1 prior
tudy, vaccine-speciﬁc antibody concentrations were
hown to be higher in autoPBSCT patients compared
ith autoBMT patients after receipt of multiple doses
f HIB-conjugate and tetanus toxoid vaccines within
he ﬁrst 2 years after transplantation [28]. In contrast,
study that compared inﬂuenza, pneumococcal, and
etanus toxoid antibody responses after a single dose
f each vaccine found no signiﬁcant differences be-
ween autoPBSCT patients and autologous BMT pa-
ients [29]. The difference in the ﬁndings from these
tudies could be related to the timing of immunization
nd the number of vaccine doses administered after
ransplantation, because these factors have been
hown to affect antibody responses [30,31]. There-
ore, we speculate that the ability to detect signiﬁcant
ifferences in pneumococcal antibody concentrations
etween the 2 immunization groups within the ﬁrst
ear after transplantation may be partly related to
nhanced recovery of humoral immunity after auto-
BSCT compared with autologous BMT.
Clinical factors associated with higher pneumococcal
ntibody concentrations to vaccine serotypes after trans-
lantation included being in the group immunized be-
ore stem cell collection and having higher baseline
neumococcal antibody concentrations. The signiﬁcant
ifferences in baseline serotype-speciﬁc antibody con- m
20entrations between patients immunized 7 to 10 days
efore stem cell collection compared with patients not
mmunized before stem cell collection were not ex-
ected, because the groups were randomized. The most
ikely explanation for this ﬁnding is the signiﬁcant inter-
al difference between the groups in the timing of the
aseline sample collection relative to the date of stem cell
ollection. The mean interval difference between the
roups was 7.6 days; patients in the group not immu-
ized before stem cell collection had their baseline sam-
le drawn closer to the date of stem cell collection.
inear regression analyses, stratiﬁed by immunization
roup, of baseline antibody concentrations relative to the
ime of their collection before stem cell harvest showed
decline in antibody concentrations for both groups as
he date of stem cell collection approached. The reason
or the decline in antibody concentrations when mea-
ured close to or at the time of stem cell collection is not
lear. Possible explanations may be the effect of prior
hemotherapy used to treat underlying disease on anti-
ody concentrations over time or the effect of mobiliza-
ion techniques before stem cell collection.Most patients
ho underwent PBSC collection were mobilized with
yclophosphamide followed by G-CSF before stem cell
ollection. G-CSF has been shown to have immuno-
odulatory effects on cytokine secretion and to affect
mmune responses [32,33]. Despite the limitation in our
tudy design of obtaining baseline serum samples for the
immunization groups at different times before stem
ell collection, the variable of being in the group immu-
ized before stem cell collection was independently as-
ociated with higher pneumococcal antibody concentra-
ions after transplantation, particularly at 3 and 6
onths.
In summary, ﬁndings from this study support a
ositive effect of immunization before stem cell
ollection on antigen-speciﬁc antibody responses
licited with posttransplantation immunization.
hese results also demonstrate that autoHCT pa-
ients can tolerate and respond to multiple doses of
accine given within the ﬁrst year after transplan-
ation. An approach to immunize autoHCT patients
efore stem cell collection and/or within a year of
ransplantation may be useful for other infectious
iseases or tumor vaccine strategies. A signiﬁcant
eduction in the occurrence of herpes zoster within
2 months after transplantation was seen in auto-
CT patients immunized with an inactivated vari-
ella vaccine within 30 days of HCT regardless of
pheresis followed by additional doses of vaccine at
0, 60, and 90 days after HCT [34]. Investigations
f early immunization after stem cell reinfusion
ith autologous dendritic cells pulsed with tumor-
peciﬁc antigens or tumor proteins conjugated to an
djuvant are ongoing, and ﬁndings from initial stud-
es are promising [35,36]. Our data suggest that a
ore immunogenic strategy to prevent pneumococ-
c
w
3
t
e
a
v
p
A
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
Pneumococcal Conjugate Immunization in Autologous HCT
Bal disease after autoHCT includes immunization
ith pneumococcal conjugate vaccine beginning at
months after transplantation and that immuniza-
ion before stem cell collection should be consid-
red. Future studies will need to address the utility
nd timing of subsequent immunization with 23-
alent pneumococcal polysaccharide vaccine to ex-
and serotype coverage.
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